Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 81,457 shares, a growth of 125.6% from the August 15th total of 36,102 shares. Based on an average trading volume of 227,768 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the shares of the company are sold short.
Analyst Ratings Changes
A number of brokerages have recently issued reports on OBX. Lifesci Capital initiated coverage on shares of Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price objective for the company. TD Cowen assumed coverage on Obsidian Therapeutics in a report on Thursday, August 6th. They issued a “buy” rating on the stock. William Blair started coverage on Obsidian Therapeutics in a research report on Wednesday, September 9th. They set an “outperform” rating on the stock. Weiss Ratings started coverage on Obsidian Therapeutics in a research report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Finally, Piper Sandler assumed coverage on Obsidian Therapeutics in a report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 price target for the company. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.50.
Get Our Latest Research Report on Obsidian Therapeutics
Obsidian Therapeutics Trading Down 6.1%
Obsidian Therapeutics Company Profile
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than Obsidian Therapeutics
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
